CTRI/2019/05/019199已完成未知
To Study The Effect Of Saroglitazar On Non-Alcoholic Fatty Liver Disease In Patients With Diabetic Dyslipidemia: An Open Longitudinal Observational Cohort Study - SAFE
Dept of Gastroenterology0 个研究点目标入组 107 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 107
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •1.Age between 18-70 years
- •2.Diabetes and Dyslipidemia requiring medical treatment
排除标准
- •1.Chronic viral hepatitis
- •2.Significnt alcohol intake
- •3.Uncontrolled thyroid disease
- •4.Active cardio-pulmonary disease.
- •5.Current/past history of malignancy.
- •6.Chronic liver disease or chronic kidney disease (CKD).
研究者
相似试验
已完成
不适用
Therapeutic efficacy of Pioglitazone for Non-Alcoholic Fatty Liver Desease(NAFLD) patients with impaired glucose tolerance or type 2 diabetesJPRN-UMIN000001035Tohoku University Graduate School of Medicine100
已完成
3 期
onalcoholic fatty liver treatmentIRCT20161210031316N2Arak University of Medical Sciences42
招募中
4 期
Saroglitazar (LipaglynTM) on Postprandial Lipemia in Type 2 Diabetes Mellitus (PRESS XIII)CTRI/2015/06/005845Cadila Healthcare Ltd30
尚未招募
Unknown
Effect of saroglitazar in patients with diabetes mellitusCTRI/2023/09/057322JIPMER Intramural fund
进行中（未招募）
不适用
The Impact of Deferasirox on Non-Alcoholic-Steatohepatitis (NASH, a non-alcoholic fatty liver disease)To assess the clinical and biological activity of Deferasirox in patients with NASH and increased iron storage / disturbed distribution of iron on liver function and liver histologyMedDRA version: 14.0Level: LLTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2009-012916-41-DECROLLL GmbH